UKCTOCS Logo

Overview

Latest Update! 10th September 2016
Clarification with regard to UKCTOCS/UKFOCSS results following FDA
recommendation on ovarian cancer screening tests
The FDA recommends against using screening tests for ovarian cancer screening:
FDA Safety Communication
(http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm519413.htm)
  1. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial involving 202,000 women has shown that it is possible to detect ovarian cancer with high sensitivity, specificity, positive predictive value, acceptability and compliance using a multimodal screening strategy which combines serum CA125 interpreted using the risk of ovarian cancer algorithm, transvaginal ultrasound and clinical assessment.
  2. There was a significant increase in early stage cancers detected in the multimodal arm compared to women who had no screening. No other screening strategy has achieved this.
  3. As with other forms of cancer screening, there was unnecessary surgery but the surgical false positive rate with multimodal screening was lower than with any other prospectively evaluated screening strategy for ovarian cancer. One in four women who underwent surgery had ovarian cancer.
  4. While the multimodal screening strategy was associated with a reduction in ovarian cancer deaths on follow up to 14 years, the latter was not definitive and needs to be confirmed on follow up which is underway. The final results of this follow-up are expected in 2019.
  5. There is therefore currently insufficient evidence to recommend ovarian cancer screening in the general population.
  6. Despite this, if women at general population risk wish to access multimodal ovarian cancer screening, they should be fully informed about the risks / benefits including the true and false positive rates, true and false negative rates, the benefits of a stage shift, the risk of complications and the uncertainties around potential impact on lives saved. They need to understand that to achieve the performance described in UKCTOCS, the entire multimodal screening strategy needs to be followed.
  7. High risk women, especially those with BRCA mutations, should consider risk-reducing surgery as the primary option to manage their ovarian cancer risk.
  8. The results of the United Kingdom Familial Ovarian Cancer Screening Study (UKFOCSS) which used multimodal screening in the high risk population has been submitted for publication and is under review. It will in due course be published and will provide data on the role of ovarian cancer screening in high risk women who do not wish to undergo, or wish to delay risk-reducing surgery. 
Prof Usha Menon,1*,** Prof Ian Jacobs,1,2 *,** Prof Mahesh Parmar,3* Dr Steven J Skates,4*,** Prof Alistair J McGuire,5 Dr Andy Ryan,1* Dr  Aleksandra Gentry-Maharaj,1* Dr Matthew Burnell,1* Dr Jatinderpal Kalsi,1* Ms Lindsay Fraser,1** Dr Adam N Rosenthal1**

Affiliations:

1 Department of Women’s Cancer, Institute for Women’s Health, UCL, London W1T 7DN, UK; 2 University of New South Wales, Sydney, New South Wales 2052, Australia; 3 Medical Research Council Clinical Trials Unit at University College London, London WC2B 6NH, UK; 4 MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, MA 02114, USA; 5 Department of Social Policy, London School of Economics, London WC2A 2AE, UK

*UKCTOCS trialists **UKFOCSS trialists

Lay summary of the mortality results of UKCTOCS

The mortality results of UKCTOCS, the largest ever ovarian cancer screening trial, were published in The Lancet in December 2015. In the trial women underwent one of two forms of screening (1) multimodal screening (MMS) based on a yearly CA125 blood test interpreted using the Risk of Ovarian Cancer Algorithm (ROCA) followed by an internal (transvaginal) scan and repeat blood test if the result was abnormal (2) ultrasound screening (USS) based on a yearly internal scan which was repeated if the result was abnormal. They were offered between 7-11 annual screens. The ovarian cancer outcomes till 31st December 2014 of women in the screen groups were compared to those of women in the control (C) group who were not offered any screening. 

The trial shows for the first time that multimodal screening results in the detection of significantly more earlier stage ovarian/peritoneal cancers than no screening. It may be possible to prevent 1 in 5 (20%) ovarian cancer deaths if women undergo annual multimodal screening (MMS) but this needs to be confirmed on further follow up.

For every woman found to have ovarian cancer on screening, 2 additional women in the MMS group and 10 additional women in the USS arm had surgery where the ovaries were only found to have benign lesions or were normal. The surgical complication rate of these additional operations was around 3.1% (MMS) and 3.5% (USS) which matches the standard complication rate for such surgery. In addition, while screening did not raise anxiety, levels of worry were higher in women who had abnormal results and required additional 2nd line tests.  Rarely women had complications related to having a blood test or an internal scan such as pain, bruising or cystitis.

Our data at this point is not sufficient to recommend a National Screening Programme like for breast and cervical cancer. We estimate that further follow-up of approximately four years is required before we can confirm the reduction in deaths.  However, we remain hopeful that following this time period we will be able to provide the National Screening Committee with all the information they need to make a decision as to whether the NHS should have an ovarian cancer screening programme. 

At this point, some women may wish to seek private screening in the absence of a NHS screening programme. This individual decision will depend upon many factors including a woman's personal risk of ovarian cancer, her views on health and screening and the cost involved. Our advice is that women considering private screening should consider both the benefits and harms involved and make a fully informed decision having taken medical advice. On balance the current evidence suggests that the multimodal screening using the ROCA test has the highest sensitivity for detection of ovarian cancer, the lowest number of false positive results and results in ovarian/peritoneal cancers being picked up at earlier stage. However, one cannot be definitely sure that it saves lives.

The UKCTOCS data provide fresh impetus to continue to pursue screening as an option for reducing mortality in this most lethal of gynaecological cancers. We are greatly indebted to our trial participants, the funding agencies and the many NHS staff who have brought us so far. 

Jacobs IJ, Menon U, Ryan A. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2015; published online Dec 17. (Click the link to access the published scientific article).

A meeting was held at the Royal College of Obstetrics and Gynaecology to present the results. The meeting was recorded and can be viewed by clicking on the following link:-

https://www.youtube.com/watch?v=gD8PGK3ieyw

Various media outlets reported on the results:-

http://www.telegraph.co.uk/news/science/science-news/12056265/Screening-could-prevent-one-in-five-ovarian-cancer-deaths-study-shows.html

Link to BBC health news from 17th dec:- http://www.bbc.co.uk/news/health-35111443

http://www.express.co.uk/life-style/health/627560/Ovarian-cancer-study-screening-cut-deaths-30-per-cent

http://www.theguardian.com/science/2015/dec/17/ovarian-cancer-blood-test-could-reduce-deaths-roca

Ovarian Cancer Screening Tests: Safety Communication FDA Recommends Against Use The FDA recommends against using screening tests for ovarian cancer screening: FDA Safety Communication

(http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm519413.htm)

  1. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial involving 202,000 women has shown that it is possible to detect ovarian cancer with high sensitivity, specificity, positive predictive value, acceptability and compliance using a multimodal screening strategy which combines serum CA125 interpreted using the risk of ovarian cancer algorithm, transvaginal ultrasound and clinical assessment.
  2. There was a significant increase in early stage cancers detected in the multimodal arm compared to women who had no screening. No other screening strategy has achieved this.
  3. As with other forms of cancer screening, there was unnecessary surgery but the surgical false positive rate with multimodal screening was lower than with any other prospectively evaluated screening strategy for ovarian cancer. One in four women who underwent surgery had ovarian cancer.
  4. While the multimodal screening strategy was associated with a reduction in ovarian cancer deaths on follow up to 14 years, the latter was not definitive and needs to be confirmed on follow up which is underway. The final results of this follow-up are expected in 2019.
  5. There is therefore currently insufficient evidence to recommend ovarian cancer screening in the general population.
  6. Despite this, if women at general population risk wish to access multimodal ovarian cancer screening, they should be fully informed about the risks / benefits including the true and false positive rates, true and false negative rates, the benefits of a stage shift, the risk of complications and the uncertainties around potential impact on lives saved. They need to understand that to achieve the performance described in UKCTOCS, the entire multimodal screening strategy needs to be followed.
  7. High risk women, especially those with BRCA mutations, should consider riskreducing surgery as the primary option to manage their ovarian cancer risk.
  8. The results of the United Kingdom Familial Ovarian Cancer Screening Study (UKFOCSS) which used multimodal screening in the high risk population has been submitted for publication and is under review. It will in due course be published and will provide data on the role of ovarian cancer screening in high risk women who do not wish to undergo, or wish to delay risk-reducing surgery.

Prof Usha Menon,1*,** Prof Ian Jacobs,1,2 *,** Prof Mahesh Parmar,3* Dr Steven J Skates,4*,** Prof Alistair J McGuire,5 Dr Andy Ryan,1* Dr  Alexandra Gentry-Maharaj,1* Dr Matthew Burnell,1* Dr Jatinder Kalsi,1* Ms Lindsay Fraser,1** Dr Adam N Rosenthal1**

Affiliations:
1 Department of Women’s Cancer, Institute for Women’s Health, UCL, London W1T 7DN, UK;
2 University of New South Wales, Sydney, New South Wales 2052, Australia;
3 Medical Research Council Clinical Trials Unit at University College London, London WC2B 6NH, UK;
4 MGH Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, MA 02114, USA;
5 Department of Social Policy, London School of Economics, London WC2A 2AE, UK

*UKCTOCS trialists
**UKFOCSS trialists

Ovarian cancer is the leading cause of death from gynaecological cancers in the United Kingdom. Majority of the women are diagnosed with bulky disease that has spread beyond the ovary and 60% die within five years of diagnosis.

In this trial over 1.2 million women were invited and 202,638, postmenopausal women aged 50 and above were recruited through thirteen centres in England, Wales and Northern Ireland between 2001 and 2005. 

They were randomly assigned to two groups – (1) control group (101,359) who received no screening (to reflect the current situation in the UK) and (2) screen group who had annual screening till December 2011.

The women were screened using two tests - (1) those in the multimodal group (50,640) had a blood test for CA125, a protein which is raised in ovarian cancer.

A mathematical formula called the Risk of Ovarian Cancer algorithm then assigned risk depending of the CA125 trend.

If risk was classified as intermediate or elevated, the volunteer underwent repeat blood tests or a scan. (2) women in the ultrasound group (50,639) had an internal (transvaginal) ultrasound scan of the ovaries.

If an abnormality was seen, the scan was repeated. In both groups women had more extensive testing with referral for surgery if there was persistent abnormality. All participants were followed up for health outcomes using postal questionnaires as well as tracked through the Health and Social Care Information Centre for cancer registrations and deaths. 

ukmap
ISRCTN Number 22488978
UKCRN ID 786

Funding

MRC - Medical Research Council
NHS R&D - National Health Service Research and Development
Medical Research Council
NIHR-stamp-fund
Cancer Research UK
The Eve Appeal
Cancer Research UK The Eve Appeal

INFORMATION FOR PARTICIPANTS

As explained at the time you gave consent to take part, participation is voluntary.  You are free to withdraw from the study at any time and do not have to give a reason.  This will not affect any future care you receive.

If you wish to receive further information about the study or wish to withdraw, you can do so by contacting:

  • email: ukctocs@ucl.ac.uk
  • Dr Tindie Kalsi, Dr Andy Ryan or Professor Usha Menon, UKCTOCS Team, Gynaecological Cancer Research Centre, Institute for Women’s Health, UCL, Maple House, 149 Tottenham Court Road, London W1T 7DN
  • Tel: 020 3447 2125

Design / Intervention

Randomised controlled trial with three arms:

  1. A control group (no screening).
  2. A multimodal group (annual screening with serum CA 125 as the primary test and CA125 and ultrasound as the secondary test).
  3. An ultrasound group (annual screening with ultrasound as the primary test and repeat ultrasound in 6-8 weeks as the secondary test).

Objectives / Aims

Objective 1

  • To establish the impact of screening on ovarian cancer mortality

Objective 2

  • To determine the physical morbidity of ovarian cancer screening.
  • To determine the resource implications of screening.
  • To record the psychological consequences of screening.
  • To assess the feasibility of population screening for ovarian cancer as reflected by uptake of invitations and compliance rates with annual screening.
  • To compare the performance of two screening strategies for ovarian cancer

Objective 3

  • To establish a serum bank for future assessment of novel tumour markers.

Primary outcome

Ovarian cancer mortality at 7 years after randomisation.

Inclusion / Exclusion Criteria

Inclusion criteria

  1. Age 50-74 years:
  2. Postmenopausal: Either (a) >12 months amenorrhoea following a natural menopause or hysterectomy, or (b) >12 months of hormone replacement therapy (HRT) commenced for menopausal symptoms.

Exclusion criteria

  1. History of bilateral oophorectomy.
  2. Currently active non-ovarian malignancy. Women who have a past history of malignancy will only be eligible if (a) they have no documented persistent or recurrent disease and (b) have not received treatment for >12 months.
  3. Women who have had an ovarian malignancy in the past.
  4. Women at high risk of ovarian cancer due to familial predisposition as defined by the eligibility criteria for the UKCCCR Familial Ovarian Cancer Screening Study.
  5. Women participating in other ovarian cancer screening trials

Recruitment

  • 1,243,282 women aged 50-74 identified from Heath Authority age/sex registers were invited between April 2001 and September 2005.
  • 205,090 women attended for recruitment.
  • 202,638 were randomised

    • 101,359 to control arm.
    • 50,640 to multimodal screening.
    • 50,639 to ultrasound screening.

Screening

Women allocated to the screen arms underwent 7-11 annual screens between April 2001 and December 2011.

Biobank

  1. Over 500,000 serum samples (single sample taken at recruitment for all 3 groups and then annual serial sample taken from multimodal group
  2. Over 350,000 examination transvaginal ultrasound DICOM images

Trial duration

Routine annual screening: April 2001 - December 2011

Follow-up: Till 2018

Primary outcome analysis: 2014

gcrcteam

Principal Investigators

Professor Ian Jacobs University College London / University of Manchester / University of New South Wales, Sydney, Australia

Professor Usha Menon

University College London

Co-Investigators

Professor Mahesh Parmar MRC Clinical Trials Unit, UCL
Professor Steven Skates MGH Cancer Center and Harvard Medical School, Boston
Professor Stuart Campbell Create Health
Professor Alistair McGuire LSE Health and Social Care
Professor Lesley Fallowfield Cancer Research UK Sussex Psychosocial Oncology

Coordinating Centre Research Team

Contact Telephone: 020 3447 2125

Dr Tindie Kalsi
Project Manager
Dr Andy Ryan Data Manager
Ms Susan Davies Senior Research Sister
Dr Aleksandra Gentry-Maharaj Senior Research Associate and Safety Officer
Dr Sophia Apostolidou Research Associate
Dr Matthew Burnell Statistician
Mr Robert Liston Senior Software Analyst
Dr Anne Dawnay Consultant Clinical Biochemist
Eur Ing Will Stott Creator of Ultrasound Record Archive / Researcher
Dr Aarti Sharma Clinical Research Associate
Dr Mariam Habib Research Associate
Mrs Gwendolen Fletcher National Lead sonographer
Karen Sibley Project Co-ordinator
Dr Rachel Hallett Research Associate
Sara Lewis Research Associate
Susie Grant Research Associate
Lanre Odunlami Software Analyst
Fiona Warburton Statistician

Admin Team

Sheila Spicer
Receptionist/Administrator
Katharine Bailey Administrator
Jennifer Sheals Administrator
Lucy Connelly Administrator
Tracy Roberts Admin support
Yvonne Wold Secretary/Administrator
Charlotte Spicer Administrator
Lisa Hinton Administrator
Althea Dyer Administrator

Laboratory Team

Richard Gunu BMS1
Kirstin Tamm Laboratory technician
Mumtaz Ahmed Laboratory technician
Josephine Cunningham Laboratory technician
Jeremy Ford Laboratory Manager
Theresa Goodall Laboratory technician
Nuno Alves Laboratory technician
Mary Pamboris Laboratory technician
Tasmin Akbar Laboratory technician
Linda Hadcocks Laboratory Manager
Martin Bacon Laboratory technician
UKCTOCS CC and RC Leads 2015

Belfast

UKCTOCS Department
93 Lisburn Road
Belfast City Hospital
Belfast, BT9 7BD
Start Date: 11-03-2002
Recruitment: 13,584
Research Nurse / Co-ordinator
Adrina O'Donnell
Research Nurse / Phlebotomist Stevie Marley
Phlebotomist Margaret Young
Lead Radiographers Adneska Zawislak
Principal Investigator Stephen Dobbs

Bristol

Directorate of Obstetrics Gynaecology and ENT
St. Michael's Hospital
Southwell Street
Bristol, BS2 8EG
Start Date: 24-10-2001
Recruitment: 16,538
Research Trial Manager/Phlebotanist
Carole Shahin
Associate Nurse Lizzie Langdon
Sonographers    K.Mc Millen
Sally Sizer
Verity John Katherine Gale
Fiona Anderson
Principal Investigator John Murdoch

Cardiff (University of Wales College of Medicine)

Department of Obstetrics and Gynaecology
Heath Park
Cardiff CF14 4XN
Start Date: 22-04-2002
Recruitment: 16,758
Research Sister Debbie Williams
Ultrasonographers H. Clarke,A. Rogers
S.Underwood
R .Jones
Clerical Officer Gaynor Alexander
Principal Investigator Nazar Amso

Derby

Ovarian Screening Department
Derby City General Hospital
Uttoxeter Road
Derby, DE22 3NE
Start Date: 16-09-2002
Recruitment: 14,920
Research Nurse
Samantha Crockett
Clerk A Ferguson
Consultant Radiographer Gillian Turner
Principal Investigator HowardJenkins

Gateshead

Northern Gynaecological Oncology Centre
Queen Elizabeth Hospital
Sheriff Hill
Gateshead
Tyne & Wear, NE9 6SF
Start Date: 18-04-2001
Recruitment: 17,323
Research Nurse
Rachel Mugnai
Clerk Grace Rudge
Principal Investigator Keith Godfrey

Liverpool

Liverpool Womens Hospital
Crown Street
Liverpool, L8 7SS
Start Date: 16-07-2001
Recruitment: 10,097
Research Nurse
Joyce Ward
Principal Investigators
Johnathon Herod

London - Royal Free

Ovarian Screening Unit
5th Floor - Royal Free Hospital
Pond Street
London, NW3 2QG
Start Date: 22-10-2001
Recruitment: 16,830
Research Nurse
Laura Crosby
Clerk Sally Martin
Phlebotomist Sadhna Bhola
Ultrasonographers Beena Heyer
Elaine Ferrier
Anne Marie Mackins
Principal Investigator Tim Mould

London - St Barts

Ovarian Cancer Screening
Women's Outpatients - 2nd floor Main Outpatients
St. Bartholomew's Hospital
London EC1A 7BE
Start Date: 17-06-2001
Recruitment: 19.834
Research Nurse
Laura Crosby
Clerk Sally Martin
Phlebotomist Sadhana Bohla
Ultrasonographers Elaine Ferrier
Vera Medic
Principal Investigators David Oram

Manchester

The Wellcome Trust Clinical Research Facility
Manchester Royal Infirmary
Grafton Street
Manchester, M13 9WL
Start Date: 10-06-2002
Recruitment: 16,518
Research Nurse Trish Morgan
Associate Nurse Pavenjit Nandhra
Melanie Dadkha -Taeidy
Clerks Suzanne Heywood
Susan Gray
Jennifer Chileshe
Consultant Radiologist Dr Jane Hawnauer
Principal Investigator Mr Mourad Seif

Middlesbrough

Ovarian Screening Office
James Cook University Hospital
Marton Road
Middlesbrough
Cleveland TS4 3BW
Start Date: 10-02-2003
Recruitment: 9,926
Radiographers

Vanessa Chadwick
Louise Prentis

Principal Investigator Derek Cruikshank

N. Wales - Llandudno

Llandudno General Hospital
Llandudno
Wales, LL30 1LB
Start Date: 27-05-2002
Recruitment: 14,338
Research Nurses
Denise Longley & Carol Chapman
Clerk Sandra Huffen
Ultrasonographer Sue Hogg
Principal Investigator Simon Leeson

Nottingham

Nottingham City Hospital Trust Hucknall Road Nottingham, NG5 1PB Start Date: 23-07-2001
Recruitment: 16,781
Administrator
Elaine Bailey
Phlebotomists Cheryl Hewitt
Nicole ward
Chief Radiologist Cathy Bown
Principal Investigator Karin Williams

Portsmouth

Blendworth One, West Wing Corridor
St. Mary's Hospital
Milton Road
Portsmouth, PO3 6AD
Start Date: 11-09-2001
Recruitment: 19,191
Research Nurse
Mary Anderson
Phlebotomist Julie Pryke
Clerk June Burns
Data co-ordinator Caroline West
Principal Investigator Rob Woolas
UKCTOCS DMEC TSC 2015

Trial Steering Committee

Name
Role
Affiliation
Professor David Luesley (Chair) Independent Chairman Professor of Gynaecological Oncology, Birmingham (retired)
Professor Jack Cuzick Independent Member Head of Mathematics and Statistics (Cancer Research UK)
Professor Julietta Patnick Independent Member Director, NHS Cancer Screening Programmes
Ms Louise Bayne Independent Member & Lay Representative Director, Ovacome
Professor Ian Jacobs Principal Investigator President and Vice-Chancelloe, UNSW Austrailia
Professor Max Parmar Co - Investigator Head, Cancer Division, MRC Clinical Trials Unit
Professor Lesley Fallowfield Principal Investigator
(Psychosocial Study)
Director, Sussex Psychosocial Oncology Group (Cancer Research UK)
Professor Usha Menon Trial Coordinator/ Co-investigator Head of Gynaecological Cancer Research Centre, Institute of Women's Health, UCL

Data Monitoring and Ethics Committee (DMEC)

Name Affiliation
Professor Peter Boyle, FRSE (Chair)
President
International Prevention Research Institute
Lyon, France
Dr Susanne Kjaer, MD., DMSc. Head of Department
Dept. of Virus, Hormones and Cancer
Institute of Cancer Epidemiology
Danish Cancer Society
Copenhagen
Professor Dr A. P. M. Heintz Department Obstetrics and Gynaecology
University Hospital Utrecht
The Netherlands
Dr Edward L. Trimble, MD MPH Associate Professor
The Johns Hopkins Hospital
Baltimore, Maryland, USA

Trial Management Committee

Name
Role
Professor Ian Jacobs (Chair) Principal Investigator
Professor Usha Menon Co-Investigator / Trial Co-ordinator
Professor Max Parmar Co-Investigator / Trial Statistician
Dr Steve Skates Co-Investigator
Professor Stuart Campbell Co-Investigator
Professor Ali McGuire Co-Investigator
Mr Tim Mould Centre Lead, Royal Free, London
Mr Rob Woolas Centre Lead, Portsmouth
Dr Tindie Kalsi Project Manager
Dr Andy Ryan Data Manager
Dr Aleksandra Gentry-Maharaj Senior Research Associate and Safety Officer
Miss Susan Davies Senior Research Sister
Dr Justine Kilkerr Psychosocial Study Co-ordinator

Ultrasound Sub-committee

Name
Affiliation
Professor Usha Menon (Chair) GCRC, IfWH, UCL
Professor Stuart Campbell Create Health Clinic, London, UK
Mrs Gwendolen Fletcher GCRC, IfWH, UCL
Mr Nazar Amso Department of Obstetrics and Gynaecology, University of Wales College of Medicine, Heath Park,Cardiff, UK
Mr Mourad Seif Academic Unit of Obstetrics and Gynaecology, St. Mary’s Hospital, Manchester, UK
Dr Gillian Turner Department of Imaging, Royal Derby Hospital, Derby, UK
Dr Carol Brunell Department of Clinical Radiology, UCLH, London, UK
Mrs Kathy Ford St Helens and Knowsley NHS Trust Maternity Ultrasound, Whiston Hospital, Prescot,Merseyside,UK
Dr Rani Rangar Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK
Dr Alex Gentry-Maharaj GCRC, IfWH, UCL
Dr Tindie Kalsi GCRC, IfWH, UCL
Dr Andy Ryan GCRC, IfWH, UCL

Outcome Review Committee

Name
Affiliation
Dr Naveena Singh Consultant Pathologist, Barts Health NHS Trust
Dr Liz Banjamin Consultant Pathologist, UCH NHS Trust
Prof Martin Widschwendter Head, Women's Cancer, IfWH, UCL
Ms. Karina Reynolds Consultant Gynaecological Oncologist, Barts Health NHS Trust

PUBLICATIONS

  1. Jenkins, V, Fallowfield L, Langridge C, Barrett J, Ryan A, Jacobs I, Kilkerr J, Menon U, and Farewell V. Psychosocial Factors Associated with Withdrawal from the United Kingdom Collaborative Trial of Ovarian Cancer Screening after 1 Episode of Repeat Screening. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 28 Jul 2015.
  2. Thomas DS, Fourkala E-O, Apostolidou S, Gunu R, Ryan A, Jacobs I, Menon U, Alderton W, Gentry-Maharaj A*, Timms JF* (*joint last). Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer 2015 Jul 14;113(2):268-74. doi: 10.1038/bjc.2015.202. Epub 2015 Jun 2. PubMed PMID: 26035703.
  3. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J2, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.
  4. Sharma A, Burnell M, Gentry-Maharaj A, Campbell S, Amso NN, Seif MW, Fletcher  G, Brunell C, Turner G, Rangar R, Ryan A, Jacobs I, Menon U. Quality Assurance and its impact on ovarian visualisation rates in the multicentre United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound Obstet Gynecol 2015 Jun 19. doi: 10.1002/uog.14929. [Epub ahead of print] PubMed PMID: 26095052.
  5. Gentry-Maharaj A, Karpinskyj C, Glazer C, Burnell M, Ryan A, Fraser L, Lanceley A, Jacobs I, Hunter MS, Menon U. Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study. Menopause 2015 Apr;22(4):384-90.
  6. Bailey K, Ryan A, Apostolidou S, Fourkala E-O, Burnell M, Gentry-Maharaj A, Kalsi J, Parmar M, Jacobs I, Pikhart H, Menon U. Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health 2015 Mar 17;15:253. doi: 10.1186/s12889-015-1609-5. PubMed PMID: 25848938; PubMed Central PMCID: PMC4367890.
  7. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala E-O, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, Zaikin A, Smith RC, Jacobs IJ, Menon U, Costello E, Pereira SP, Timms JF. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 2015 Feb 1;21(3):622-31. doi: 10.1158/1078-0432.CCR-14-0365. Epub 2014 Jun 17. PubMed PMID: 24938522; PubMed Central PMCID: PMC4181906.
  8. Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala E-O, Gentry-Maharaj A, Pereira SP, Jacobs I, Cox TF, Greenhalf W, Timms JF, Sutton R, Neoptolemos JP, Costello E. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. J Proteomics 2015 Jan 15;113:400-2. PubMed PMID: 25316052.
  9. Timms JF, Arslan-Low E, Kabir M, Worthington J, Gentry-Maharaj A, Camuzeaux S, Sinclair J, Szaub J, Afrough B, Fourkala E-O, Podust V, Kronenberg F, Cubizolles M, Fung ET, Menon U and Jacobs I. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics Clinical Applications 2014 Dec;8(11-12):982-93. doi: 10.1002/prca.201400063. Epub 2014 Nov 10.
  10. Fourkala E-O*, Burnell M*, Cox C, Ryan A, Salter LC, Gentry-Maharaj A, Parmar M, Jacobs I, Menon U (*joint). Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ open 2014 Oct 6;4(9):e005400.
  11. Anjum S*, Fourkala E-O*, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, Menon U, Widschwendter M (*joint). A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome medicine 2014 Jun 27;6(6):47.
  12. Fraser L, Burnell M, Salter LC, Fourkala E-O, Kalsi J, Ryan A, Gessler S, Gidron Y, Steptoe A, Menon U. Identifying hopelessness in population research: a validation study of two brief measures of hopelessness. BMJ Open 2014 May 30;4(5):e005093.
  13. Barrett J, Jenkins V, Farewell V, Menon U, Jacobs I, Kilkerr J, Ryan A, Langridge C, Fallowfield L; UKCTOCS trialists. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG: an international journal of obstetrics and gynaecology 2014 May 28;121(9):1071-9.
  14. Pedersen JW*, Gentry-Maharaj* A, Nostdal A, Fourkala E-O, Dawnay A, Burnell M, Zaikin A, Burchell J, Papadimitriou JT, Clausen H, Jacobs I, Menon U*, Wandall HH* (*joint). Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International journal of cancer Journal international du cancer 2014 May 1;134(9):2180-88.
  15. Gentry-Maharaj A, Taylor H, Kalsi J, Ryan A, Burnell M, Sharma A, Apostolidou S, Campbell S, Jacobs I, Menon U. Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ open. 2014;4(3):e004421.
  16. Pedersen JW*, Gentry-Maharaj* A, Nostdal A, Fourkala EO, Dawnay A, Burnell M, Zaikin A, Burchell J, Papadimitriou JT, Clausen H, Jacobs I, Menon U*, Wandall HH* (*joint). Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International journal of cancer Journal international du cancer. 2014 May 1;134(9):2180-88.
  17. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, Zaikin A, Smith RC, Jacobs I, Menon U, Costello E, Pereira SP, Timms JF. Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis with pancreatic cancer: implications for early disease detection. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Jun 17.
  18. Fourkala EO*, Burnell M*, Cox C, Ryan A, Salter LC, Gentry-Maharaj A, Parmar M, Jacobs I, Menon U (*joint). Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ open. 2014;4(9):e005400.
  19. Anjum S*, Fourkala EO*, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, Menon U, Widschwendter M (*joint). A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome medicine. 2014;6(6):47.
  20. Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A, Pereira SP, Jacobs I, Cox TF, Greenhalf W, Timms JF, Sutton R, Neoptolemos JP, Costello E. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. Journal of proteomics. 2014 Oct 12;113C:400-2.
  21. Fraser L, Burnell M, Salter LC, Fourkala EO, Kalsi J, Ryan A, Gessler S,Gidron Y, Steptoe A, Menon U. Identifying hopelessness in population research: a validation study of two brief measures of hopelessness. BMJ open 2014;4(5):e005093.
  22. Barrett J, Jenkins V, Farewell V, Menon U, Jacobs I, Kilkerr J, Ryan A, Langridge C, Fallowfield L; UKCTOCS trialists. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG : an international journal of obstetrics and gynaecology 2014;121(9):1071-9.
  23. Gentry-Maharaj A, Fourkala EO, Burnell M, Ryan A, Apostolidou S, Habib M, Sharma A, Parmar M, Jacobs I, Menon U. Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. British journal of cancer 2013;109(11):2875-9.
  24. Burford B*, Gentry-Maharaj A*, Graham R*, Allen D, Pedersen JW, Nudelman AS, Blixt O, Fourkala EO, Bueti D, Dawnay A, Ford J, Desai R, David L, Trinder P, Acres B, Schwientek T, Gammerman A, Reis CA, Silva L, Osorio H, Hallett R, Wandall HH, Mandel U, Hollingsworth MA, Jacobs I, Fentiman I, Clausen H, Taylor-Papadimitriou J*, Menon U*, Burchell JM* (*joint). Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British journal of cancer. 2013 May 28;108(10):2045-55.
  25. Sharma A, Burnell M, Gentry-Maharaj A, Campbell S, Amso NN, Seif MW, Fletcher G, Brunel C, Turner G, Rangar R, Ryan A, Jacobs I, Menon U, United Kingdom Collaborative Trial of Ovarian Cancer S. Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2013 Oct;42(4):472-7.
  26. Gentry-Maharaj A*, Sharma A*, Burnell M, Ryan A, Amso NN, Seif MW, Turner G, Brunell C, Fletcher G, Rangar R, Fallowfield L, Campbell S, Jacobs I, Menon U. Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Ultrasound Obstet Gynecol. 2013 Jan;41(1):73-9.
  27. Pedersen JW*, Gentry-Maharaj A*, Fourkala E-O, Dawnay A, Burnell M, Zaikin A, Pedersen AE, Jacobs I, Menon U**, Wandall H** Early detection of cancer in the general population - a blinded case control study of p53 auto-antibodies in colorectal cancer. Br J Cancer. 2013 Jan 15;108(1):107-14.
  28. Devetyarov D, Nouretdinov I, Burford B, Camuzeaux S, Gentry-Maharaj A, Tiss A, Smith C, Luo Z, Chervonenkis A, Hallett R, Vovk V, Waterfield M, Cramer R, Timms JF, Sinclair J, Menon U, Jacobs I, Gammerman A Conformal predictors in early diagnostics of ovarian and breast cancers. Progress in Artificial Intelligence.Volume 1, Number 3 (2012), 245-257
  29. Sharma A, Apostolidou S, Burnell M, Campbell S, Habib M, Gentry-Maharaj A, Campbell S, Amso N, Seif MW, Fletcher G, Singh N, Benjamin E, Brunell C, Turner G, Rangar R,Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R,Murdoch J, Dobbs S, Leeson S, Cruickshank D, Fourkala E-O, Ryan A, Parmar M, Jacobs I*, Menon U*. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound Obstet Gynecol 2012;40(3):338-44.
  30. Fourkala E-O, Gentry-Maharaj A, Burnell M, Ryan A, Manchanda R, Dawnay A, Jacobs I, Widschwendter M, Menon U. Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer 2012;106(12):1910-6.
  31. Sharma A, Gentry-Maharaj A, Burnell M, Fourkala EO, Campbell S, Amso N, Seif MW, Fletcher G, Brunel C, Turner G, Rangar R, Ford K, Ryan A, Jacobs I, Menon U for UKCTOCS. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. Bjog 2012;119(2):207-19.
  32. Hunter M, Gentry-Maharaj A, Lanceley A, Fraser L, Burnell M, Ryan A, Fraser L, Jacobs I, Menon U. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. BJOG : an international journal of obstetrics and gynaecology, 2012. 119(1): p. 40-50
  33. Hamajima N, Hirose K, Tajima K, Rohan T, Friedenreich CM, Calle EE, Gapstur SM, Patel AV, Coates RJ, Liff JM, Talamini R, Chantarakul N, Koetsawang S, Rachawat D, Marcou Y, Kakouri E, Duffy SW, Morabia A, Schuman L, Stewart W, Szklo M, Coogan PF, Palmer JR, Rosenberg L, Band P, Coldman AJ, Gallagher RP, Hislop TG, Yang P, Cummings SR, Canfell K, Sitas F, Chao P, Lissowska J, Horn-Ross PL, John EM, Kolonel LM, Nomura AMY, Ghiasvand R, Hu J, Johnson KC, Mao Y, Beral V, Bull D, Callaghan K, Crossley B, Goodill A, Green J, Hermon C, Key T, Lindgard I, Liu B, Pirie K, Reeves G, Collins R, Doll R, Peto R, Bishop T, Fentiman IS, De Sanjose S, Gonzalez CA, Lee N, Marchbanks P, Ory HW, Peterson HB, Wingo P, Ebeling K, Kunde D, Nishan P, Hopper JL, Eliassen H, Hankinson S, Gajalakshmi V, Martin N, Pardthaisong T, Silpisornkosol S, Theetranont C, Boosiri B, Chutivongse S, Jimakorn P, Virutamasen P, Wongsrichanalai C, Neugut A, Santella R, Baines CJ, Kreiger N, Miller AB, Wall C, Tjonneland A, Jorgensen T, Stahlberg C, Pedersen AT, Flesch-Janys D, Hakansson N, Cauley J, Heuch I, Adami HO, Persson I, Weiderpass E, Magnusson C, Chang-Claude J, Kaaks R, McCredie M, Paul C, Skegg DCG, Spears GFS, Iwasaki M, Tsugane S, Anderson G, Daling JR, Hampton J, Hutchinson WB, Li CI, Malone K, Mandelson M, Newcomb P, Noonan EA, Ray RM, Stanford JL, Tang MTC, Thomas DB, Weiss NS, White E, Izquierdo A, Viladiu P, Fourkala EO, Jacobs I, Menon U, Ryan A, Cuevas HR, Ontiveros P, Palet A, Salazar SB, Aristizabal N, Cuadros A, Tryggvadottir L, Tulinius H, Riboli E, Andrieu N, Bachelot A, Le MG, Bremond A, Gairard B, Lansac J, Piana L, Renaud R, Clavel-Chapelon F, Fournier A, Touillaud M, Mesrine S, Chabbert-Buffet N, Boutron-Ruault MC, Wolk A, Torres-Mejia G, Franceschi S, Romieu I, Boyle P, Lubin F, Modan B, Ron E, Wax Y, Friedman GD, Hiatt RA, Levi F, Kosmelj K, Primic-Zakelj M, Ravnihar B, Stare J, Ekbom A, Erlandsson G, Beeson WL, Fraser G, Peto J, Hanson RL, Leske MC, Mahoney MC, Nasca PC, Varma AO, Weinstein AL, Hartman ML, Olsson H, Goldbohm RA, van den Brandt PA, Palli D, Teitelbaum S, Apelo RA, Baens J, de la Cruz JR, Javier B, Lacaya LB, Ngelangel CA, La Vecchia C, Negri E, Marubini E, Ferraroni M, Pike MC, Gerber M, Richardson S, Segala C, Gatei D, Kenya P, Kungu A, Mati JG, Brinton LA, Freedman M, Hoover R, Schairer C, Ziegler R, Banks E, Spirtas R, Lee HP, Rookus MA, van Leeuwen FE, Schoenberg JA, Graff-Iversen S, Selmer R, Jones L, McPherson K, Neil A, Vessey M, Yeates D, Mabuchi K, Preston D, Hannaford P, Kay C, McCann SE, Rosero-Bixby L, Gao YT, Jin F, Yuan J-M, Wei HY, Yun T, Zhiheng C, Berry G, Cooper Booth J, Jelihovsky T, MacLennan R, Shearman R, Hadjisavvas A, Kyriacou K, Loisidou M, Zhou X, Wang Q-S, Kawai M, Minami Y, Tsuji I, Lund E, Kumle M, Stalsberg H, Shu XO, Zheng W, Monninkhof EM, Onland-Moret NC, Peeters PHM, Katsouyanni K, Trichopoulou A, Trichopoulos D, Tzonou A, Baltzell KA, Dabancens A, Martinez L, Molina R, Salas O, Alexander FE, Anderson K, Folsom AR, Gammon MD, Hulka BS, Millikan R, Chilvers CED, Lumachi F, Bain C, Schofield F, Siskind V, Rebbeck TR, Bernstein LR, Enger S, Haile RW, Paganini-Hill A, Ross RK, Ursin G, Wu AH, Yu MC, Ewertz M, Clarke EA, Bergkvist L, Anderson GL, Gass M, O'Sullivan MJ, Kalache A, Farley TMM, Holck S, Meirik O, Fukao ACollaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet. Oncology 2012;13(11):1141-51
  34. Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A, Widschwendter M, Lichtenberg-Fraté H, Menon U. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocrine-related cancer 2012;19(2):137-47.
  35. Timms JF, Menon U, Devetyarov D, Tiss A, Camuzeaux S, McCurrie K, Nouretdinov I, Burford B, Smith C, Gentry-Maharaj A, Hallett R, Ford J, Luo Z, Vovk V, Gammerman A, Cramer R and Jacobs I. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks. Cancer Genomics Proteomics 2011;8(6):289-305.
  36. Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J, ,Skates S, Parmar M, Jacobs I, Menon U. Impact On Mortality And Cancer Incidence Rates Of Using Random Invitation From Population Registers For Recruitment To Trials. Trials, 2011. 12: p. 61.
  37. Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif M, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Skates SJ, Fallowfield L, Parmar M, Campbell S, Menon U. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. The lancet oncology, 2011. 12(1): p. 38-48.
  38. Fallowfield L, Fleissig A, Barrett J, Menon U, Jacobs I, Kilkerr J, Farewell V; UKCTOCS Trialists (Collaborators Jacobs I, Menon U, Campbell S, Fallowfield L, Skates SJ, Parmar M, McGuire A, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, Luesley D, Cuzick J, Patnick J, Cheng KK, Bayne L, Law K, Finney K, Gentry-Maharaj A, Burnell M, Ryan A, Kalsi J, Davies S, Fletcher G, Apostolidou S, Liston R.) Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer. 2010 Aug 10;103(4):454-61. doi: 10.1038/sj.bjc.6605809. Epub 2010 Jul 20.
  39. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates S, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The lancet oncology, 2009. 10(4): p. 327-40.
  40. Gammerman A, Vovk V, Burford B, Nouretdinov I, Luo Z, Chervonenkis A, Waterfield M, Cramer R, Tempst P, Villanueva J, Kabir M, Camuzeaux S, Timms J, Menon U and Jacobs I. Serum Proteomic Abnormality Predating Screen Detection of Ovarian Cancer. Comput J 2009;52(3):326-33.
  41. Widschwendter M, Lichtenberg-Frate H, Hasenbrink G, Schwarzer S, Dawnay A, Lam A, Menon U, Apostolidou S, Raum E, Stegmaier C, Jacobs IJ, Brenner H. Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. British journal of cancer 2009;101(1):160-5.
  42. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I. Recruitment to multicentre trials: lessons from UKCTOCS – Descriptive study BMJ, 2008. 337: p. a2079.
  43. Menon U, Burnell M, Sharma A, Gentry-Maharaj A, Fraser L, Ryan A, Parmar M, Hunter M, Jacobs I. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause, 2007. 14(3 Pt 1): p. 462-7.
  44. Timms JF, Arslan-Low E, Gentry-Maharaj A, Luo Z, T'Jampens D, Podust VN, Ford J, Fung ET, Gammerman A, Jacobs I, Menon, U. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clinical chemistry, 2007. 53(4): p. 645-56.

Letters to editor

  1. Sharma, A, Gentry-Maharaj A, Burnell M, Ryan A, Amso NN, Campbell S, Jacobs I, Menon U. "Reply: To Pmid 23456790."Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology May 2014; 43(5): 600-1.
  2. Gentry-Maharaj A, Kalsi J, Burnell M, Manchanda R, Menon U. Screening of symptomatic women for ovarian cancer. Lancet Oncol 2012;13(4):e138-9; author reply e39-40. (Letter to Editor)
  3. Menon U, Gentry-Maharaj A, Jacobs I. Ovarian cancer screening and mortality. JAMA 306(14):1544 (Letter to Editor)
  4. Jacobs I, Menon U. Can ovarian cancer screening save lives? The question remains unanswered. Obstet Gynecol 118(6):1209-1211, Dec 2011.
  5. Menon U. Ovarian cancer screening has no effect on disease-specific mortality. Evid Based Med. 2011 Sep 26.
  6. Menon U. Ovarian cancer: challenges of early detection. Nat Clin Pract Oncol. 2007 Sep;4(9):498-9.

BOOK CHAPTERS AND REVIEW ARTICLES

  1. Gentry-Maharaj A, Griffin M, Menon U (2015). Ovarian Cancer Prevention and Screening (in Cancer Prevention and Screening: Concepts, Principles and Controversies) Edited by Eeles, Berg, Tobias, Wiley
  2. Gentry-Maharaj A, Jacobs I, Menon U (2015). Ovarian Cancer – Tumor Markers and Screening. In Berek & Hacker’s Gynecologic Oncology, 6th edition. Wolters Kluwer. 443-463
  3. Gentry-Maharaj A, Menon U. (2014) Early detection of hereditary gynaecological cancers. In Jacobs C., Robinson,L., Webb,P (ed.) Genetics for Health Professionals in Cancer Care: from Principles to Practice. Oxford University Press.
  4. Menon U, Griffin M, Gentry-Maharaj A. Ovarian cancer screening-current status, future directions. Gynecol Oncol. [Review]. 2014 Feb;132(2):490-5.
  5. Gentry-Maharaj A, Kalsi J, Menon U. (2013) Screening for gynecologic cancers. In Patel,H., Mould,T., Joseph,J., & Delaney,C. (ed.) Pelvic Cancer Surgery: Modern breakthroughs & future advances. Springer Science.
  6. Fourkala E-O, Gentry-Maharaj A, Menon U (2013). MUC16, alias CA125 and ovarian cancer. In: Mucins and Cancer. Taylor-Papadimitriou J, Burchell JM (Eds). Future Medicine, London, UK.
  7. Kalsi JK, Manchanda R, Menon U. Screening for gynecologic cancers. Expert Review of Obstetrics & Gynecology 2013;8(2):143-60.
  8. Gentry-Maharaj A, Jacobs I, Menon U. (2012) Development and identification of tumor serum markers. In Barakat, R.R., Berchuck, A., Markman, M., Randall,M.E. (eds). Principles and Practice of Gynecologic Oncology, 6th edition. Baltimore: Lippincott Williams & Wilkins.
  9. Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 2012;26(2):243-56.
  10. Jacobs I, Menon U. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res (Phila) 2011 Mar; 4(3):299-302.
  11. Manchanda R, Jacobs IJ, Menon U. (2010) Tumour markers and screening. in Berek,j., Hacker,N (ed.) Practical Gynecologic Oncology. Philadelphia: Lippincott, Williams & Wilkin, 5th edition. 233-266.
  12. Hamilton W, Menon U. Ovarian cancer. BMJ. 2009 Nov 18;339:b4650. doi: 10.1136/bmj.b4650.
  13. Gentry-Maharaj A, Jacobs I, Menon U. (2009) Development and identification of tumor markers. in Principles and Practice of Gynecologic Oncology 5th edition (chapter 7), edited by William J Hoskins, Carlos A Perez, Robert C Young, Richard R Barakat, Maurie Markman
  14. Gentry-Maharaj A, Sharma A, Menon U. Ovarian Cancer. Review article in Geriatric Medicine, Vol 37, No 11, November 2007

CONFERENCES AND MEETINGS

2015

o    Gentry-Maharaj A. Population screening for ovarian cancer using CA125 interpreted by the risk of ovarian cancer algorithm, Mucins in Health and Disease (13th International Workshop on Carcinoma-associated Mucins), Cambridge, UK, 21st July 2015

o    Kalsi J. A risk algorithm doubles the number of ovarian cancers detected during screening in UKCTOCS compared to a single threshold rule, UCL, EGA Institute for Women’s Health 10th Annual Meeting, London, UK, 10th July 2015

o    Menon U. Ovarian screening latest news, London Cancer Gynaecology Annual Edition Open Meeting, UCL Partners, London, UK 18th June 2015

o    Menon U. Early ovarian cancer: Can we find it, can we stop it, can we afford it?, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, USA, 31st May 2015

o    Gentry-Maharaj A. Ovarian cancer screening: UKCTOCS Incidence Screening results update,

British Society for Gynaecological Imaging - Annual Scientific Meeting, Royal College of Obstetricians and Gynaecologists, London, 17th April 2015

o    Graham R. SWATH: Early detection biomarkers in ovarian cancer, SWATH Workshop, Warrington, UK, 2015

o    Graham R. SWATH in biomarker discovery, London Biological Mass Spec Discussion Group, London, UK, 2015

o    Graham R. Early detection biomarkers in ovarian cancer, East Midlands Proteomics Workshop, Warwick, UK, 2015

o    Menon U. The UKCTOCS and UKFOCSS trials – what have we learnt so far? 2nd International Ovarian Tumor Analysis Congress (IOTA 2015), Leuven, Belgium, 17th April 2015

o    Menon U. Ovarian Cancer screening – any progress? Oncology in obstetrics and gynaecology – “State of the art”, Royal Society of Medicine, London, UK, 27th Feb 2015

o    Menon U. Accelerating progress toward early detection and prevention, HHMT (Helene Harris Memorial Trust) 13th International Forum on Ovarian Cancer, Toledo, Spain, 19th Jan 2015

2014

o    Jacobs I. Quantitative proteomic discovery of candidate serum biomarkers for early detection of ovarian cancer, International Gynecologic Cancer Society, 2014

o    Menon U. Debate: Place of prophylactic salpingectomy during routine hysterectomy for benign indications,  FOR – Dr Ian Harley; AGAINST – Prof Usha Menon, RCOG (Royal College of Obstetricians and Gynaecologists) Annual Professional Development Conference, RCOG, London, UK, 19th Nov 2014

o    Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma S, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter N, Reynolds K, Campbell S, Parmar M, Skates SJ, Jacobs I. A time series algorithm doubles sensitivity of population screening for ovarian cancer in the United Kingdom Collaborative Trial Of Ovarian Cancer Screening (UKCTOCS)", IGCS Annual Meeting Melbourne Australia, 10th Nov 2014

o    Menon U. Screening for Ovarian Cancer: The way forward, 10th Biennial Ovarian Cancer Research Forum, Marsha Rivkin Centre, Seattle, USA, 8th Sept 2014

o    Gentry-Maharaj A, Ryan A, Griffin M, Taylor H, Singh N, Benjamin L, Widschwendter M, Karpinskyj C, Burnell M, Davies S, Kalsi J, Skates S, Campbell S, Parmar M, Jacobs I, Menon U on behalf of UKCTOCS. Overdiagnosis of borderline ovarian tumours in ovarian cancer screening: the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) experience, Prevention Overdiagnosis meeting, Oxford, July 2014

o    Menon U. Screening for Ovarian Cancer, Bangalore RCOG Trust, Bangalore Society of Obstetricians and Gynaecologists, Bengaluru, India, 12th July 2014

o    Menon U. Screening for Ovarian Cancer, Biennial Ovarian Cancer Symposium National University Singapore, Singapore, 27th June 2014

o    Gentry-Maharaj A, Karpinskyj C, Glazer C, Burnell M, Ryan A, Fraser L, Lanceley A, Jacobs I, Hunter MS*, Menon U* (joint last). Use and perceived efficacy of Complementary and Alternative Medicines (CAM) for menopausal symptoms after discontinuing HRT: nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) (Awarded 1st prize for the oral presentation at the meeting), Institute for Women’s Health Annual Meeting, London, 3 June 2014

o    Menon U. Ovarian and Endometrial Ultrasound Cancer Screening, 23rd European Congress of Obstetrics and Gynaecology, Glasgow, 7th May 2014

o    Menon U.  Singapore Lecture: Managing Ovarian Cancer Risk, Royal College of Obstetricians and Gynaecologists World Congress, Hyderbad, India, 29th Mar 2014

o    Menon U. Ovarian cancer symptoms - Where to set the bar? 39th Annual Conference of the Bengal Obstetric & Gynaecological Society, Kolkata, India, 18th Jan 2014

2013

o    Menon U. Genes, lifestyle, and risk of ovarian cancer, Ranbaxy Science Foundation’s 30th Round Table Conference on ‘Lifestyle and Cancer with focus on Cancer Prevention’, All India Institute of Medical Sciences,  New Delhi, India, 30th Nov 2013

o    Menon U. Ovarian cancer screening, 46th Dr Subodh Mitra Memorial Oration, Bengal Obstetric & Gynaecological Society, Chittaranjan Seva Sadan College of Obstetrics, Kolkata, 29th Nov 2013

o    Menon U. Ovarian cancer screening, Indian Cancer Conference, Delhi, 22nd Nov 2013

o    Menon U. Time series algorithms – what can we learn from UKCTOCS, Ovarian Cancer: Developing Research-Based Public Messaging on Early Detection and Screening, Cold Spring Harbour, New York,  24th Oct 2013

o    Jacobs I.  Keynote Lecture: Progress in risk prediction, diagnosis and screening for ovarian cancer, 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, 21st Oct 2013

o    Menon U. Clinical Trials - management and implementation, 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, 21st Oct 2013

o    Menon U. Screening for ovarian cancer - New insights, future directions, Gynaecological Visiting Society (GVS), London, 3rd Oct 2013

o    Menon U. Screening for ovarian cancer, Ovarian cancer, Leah Lederman lecture and Annual General Meeting, The Royal Society of Medicine, London, 25th Sep 2013

o    Menon U. Screening for ovarian cancer – new insights, future direction, Indo-UK Oncology Summit, Chennai, India, 7th Sep 2013

o    Menon U. Rethinking screening strategies for ovarian cancer, Nordic Society of Gynecologic Oncology (NSGO) Annual Meeting Stockholm, Sweden, 11th Apr 2013

o    Menon U. Update from the UKCTOCS Trial, Annual Scientific Meeting – Joint RCOG/British Society Gynaecological Imaging (BSGI), Royal College of Obstetricians and Gynaecologists, London, 15th Mar 2013

o    Gentry-Maharaj A. Volunteer acceptance of transvaginal scanning: UKCTOCS experience, Annual Scientific Meeting – Joint RCOG/British Society Gynaecological Imaging (BSGI), Royal College of Obstetricians and Gynaecologists, London, 15th Mar 2013

2012

o    Jacobs I, Ryan A, Skates S, Habib M, Apostolidou S, Singh N, Benjamin E, Gentry-Maharaj A, Burnell M, Kalsi J, Dawnay A, Sharma A, Gunu R, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, Fallowfield L, Campbell S, Parmar M, Menon U. for the UKCTOCS Group. Performance characteristics of multimodal screening with serum CA125 in the United Kingdom collaborative trial of ovarian cancer screening (UKCTOCS), 8th NCRI Cancer Conference, Liverpool, 5th Nov 2012
o    Menon U. Ovarian Cancer Screening – the future. 8th NCRI Cancer Conference, Liverpool, 5th Nov 2012
o    Menon U,  Ryan A, Campbell S, Habib M, Apostolidou S, Gentry-Maharaj A, Burnell M, Kalsi J, Sharma A, Singh S, Benjamin E, Fletcher G, Seif MW, Amso N, Burnel C, Taylor G, Rangar R, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Fallowfield L, Parmar M, Jacobs I for the UKCTOCS Group Performance characteristics of ultrasound screening in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), 8th NCRI Cancer Conference, Liverpool, 5th Nov 2012
o    Menon U. Ovarian Cancer Screening, All Party Parliamentary Group on Ovarian Cancer, The House of Commons, Westminster, London, 30th Oct 2012
o    Nouretdinov I, , Devetyarov D, Burford B,Camuzeaux S, Gentry-Maharaj A, Tiss A, Smith C, Luo Z, Chervonenkis A, Hallett R, Vovk V, Waterfield M, Cramer R, Timms JF, Jacobs I, Menon U, Gammerman A. Multiprobabilistic Venn predictors with logistic regression ( Conference Paper ) IFIP Advances in Information and Communication Technology (Volume 382 AICT, Issue PART 2, 2012, Pages 224-233, 8th International Workshop on Artificial Intelligence Applications and Innovations, AIAI 2012: AIAB, AIeIA, CISE, COPA, IIVC, ISQL, MHDW, and WADTMB;Halkidiki;8th International Workshop on Artificial Intelligence Applications and Innovations, 27-30 Sep 2012
o    Menon U. Screening for Ovarian Cancer – New Insights, Future Directions, BGCS, London, 5th Jul 2012
o    Woolas R, Talaa A, Anderson M, Garner F, Brinkmann D, Ryan A, Gentry-Maharaj A, Kalsi J, Rosenthal A, Menon U, Jacobs I. A prospective study of endometrial thickness >10mm among 3646 women aged 50-80 years undergoing transvaginal ultrasound screening for ovarian cancer, UCL EGA Institute for Women’s Health Annual Meeting, London, 21st May 2012
o    Fourkala E-O, Zaikin A, Burnell M, Gentry-Maharaj A, Jacobs I, Dawnay A, Widschwendter M, Menon U. In postmenopausal women increased levels of testosterone and follicle stimulating hormone are associated with increased breast cancer risk: a nested case-control study within UK Collaborative Trial of Ovarian-Cancer Screening (UKCTOCS), UCL EGA Institute for Women’s Health Annual Meeting, London, 21st May 2012
o    Menon U, Fourkala E-O, Burnell M, Gentry-Maharaj A, Fraser L, Ryan A, Kalsi JK, Parmar M, Jacobs I, Gessler S, Gidron Y. Association of helplessness-hopelessness and all cause/cancer-specific mortality in postmenopausal women – a prospective cohort study within the control arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). UCL EGA Institute for Women’s Health Annual Meeting, London, 21st May 2012
o    Kalsi J, Burns L, Ryan A, Fraser L, Ruff L, Philpott S, Johnson M, Habib M, Liston W, Apostolidou S, Fourkala E-O, Burnell M, Spicer S, Fletcher G, Davies S, Bailey K, Chamberlain S, Iyer R, Balogun N, Desai1 R, Mohamed S, Manchanda R, Gentry-Maharaj A, Parmar M, Fallowfield L, Campbell S, Skates S, Rosenthal A, Jacobs I, Menon U. A Tale of Two Cards, UCL EGA Institute for Women’s Health Annual Meeting, London, 21st May 2012
o    O’Brien DP, Sinclair J, Jenkinson C, Gentry-Maharaj A, Menon U, Costello E, Pereira SP, Timms JF. Quantitative Proteomic Strategies for the Discovery and Evaluation of Early Diagnostic Biomarkers for Pancreatic Cancer in Serum (GO), UCL EGA Institute for Women’s Health Annual Meeting, London, 21st May 2012
o    Gentry-Maharaj A. Does transvaginal ultrasound have any role in the screening for endometrial cancer in asymptomatic postmenopausal women? Annual Scientific Meeting and Workshops, Joint RCOG/BSGI Meeting, Royal College of Obstetricians and Gynaecologists, London, 18th May 2012
o    Menon U. UKCTOCS biobank and Abcodia, UCL Business, London, 9th March 2012

2011

o    Menon U. Quo Vadis? - Biomarker discovery for Ovarian Cancer Screening Consensus Workshop and Changing the clinical paradigm for ovarian cancer – insights from UKCTOCS, Ovarian Cancer Screening Conference, The Royal College of Physicians, London, 30th Nov 2011
o    Jacobs I. Natural history of ovarian cancer: Lead time of screening, International Conference on Ovarian Cancer Screening, London, UK 30th Nov 2011
o    Menon U. General population screening - current status and insights from the trials: UKCTOCS, International Conference on Ovarian Cancer Screening, London, UK 29th Nov 2011
o    Sharma A, Apostolidou S, Burnell M, Habib M, Gentry-Maharaj A, Campbell S, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, Fourkala E-O, Ryan A, Parmar M, Jacobs I, Menon U for United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Risk of primary ovarian cancer in asymptomatic women associated with ovarian morphology on ultrasound: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), British Gynaecological Cancer Society (BGCS) Meeting, Birmingham, November 2011
o    Alderton WK, Apostolidou S,  Barnes MR, Fourkala E-O, Gentry-Maharaj A, Jacobs I, Menon U, Ryan A, Barnes J. Reporting on cancer cases developed in a prospective cohort of volunteers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS):  Relevance of the associated serum biobank for biomarker discovery and validation, International Society of Oncology and Biomarkers Meeting, Florence, 15th-19th October 2011
o    Menon U. Screening for ovarian and endometrial cancer, 9th Congress of the European Society of Gynaecology, Copenhagen, 10th Sept 2011
o    Menon U. Effect of Screening on ovarian cancer mortality, American Society of Clinical Oncology Annual 11 Meeting, Chicago, Sept 2011
o    O’Brien DP, Sinclair J, Jenkinson C, Gentry-Maharaj A, Menon U, Costello E, Pereira S, Timms JF. Quantitative proteomic strategies for the discovery and evaluation of early diagnostic biomarkers for pancreatic cancer in serum. British Society for Proteome Research, Cambridge, June 2011
o    Menon U. The UKCTOCS Resource at UCL, Royal Free Biobank Launch, 2nd Feb 2011
o    Menon U. Serial CA125 Can Detect Ovarian Cancer in the Absence of Ultrasound Abnormalities, Helene Harris Memorial Trust 12th International Forum on Ovarian Cancer 15-19th Jan 2011

2010

o    Sandanayake NS, Andreola F, Camuzeaux S, Sinclair J, Chapman MH, Webster G, Gentry-Maharaj A, Menon U, Jacobs I, Pereira SP, Timms,JF. Serum CEACAM1 in the preclinical diagnosis of pancreatic adenocarcinoma, Digestive Week, New Orleans, 2010
o    Menon U.  Ovarian Cancer Screening - Showing it Works, At Pathways to Better Health, UCL Open Event, London 29thNov 2010
o    Menon U.  UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) - an update, 13thBiennial Meeting International Gynaecological Cancer Society at Prague, 23rd Sept 2010
o    Menon U.  Biomarkers for Screening and Early Detection of Ovarian Cancer, 38th International Society for Oncodevelopmental Biology Meeting, Munich 6th Sept 2010
o    Menon U.  High Risk Ovarian cancer Screening: Is It Useful? American Society of Clinical Oncology Annual Meeting, Chicago, 6th June 2010
o    Menon U.  Challenges of Running Large Trials at OXSFOG 2010, Wexham Park Hospital, 14th May 2010
o    Menon U. Screening for Ovarian Cancer – Biochemical Markers or Ultrasound, Joint RCOG/BSGI Meeting and Workshop, London 15th April 2010
o    Menon U. Familial Ovarian Cancer - Risk Management, AICC RCOG 25th Annual Conference, Kolkata, India. 27th Feb 2010
o    Menon U.  Interactive case discussions with Cytology, colposcopy & histology co-relation, and unedited video presentation, AICC RCOG 25th Annual Conference, Kolkata, India, 25th Feb 2010
o    Menon U. Ovarian Cancer Screening Current Trials and Unanswered Questions at OVARIAN CANCER RESEARCH FORUM, Royal College of Obstetricians and Gynaecologists, London, 11th February 2010    
o    Menon U. Better outcomes for Ovarian Cancer Generating the evidence, 8thCMC Winter Symposium Evidence for Better Health Christian Medical College, Vellore, India, 14th January 2010

2009

o    Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Findings on prevalence screening in UKCTOCS, British Medical Ultrasound Society Meeting, Edinburgh, December 2009
o    Gentry-Maharaj A. Volunteer Satisfaction Survey for UKCTOCS, British Medical Ultrasound Society Meeting, Edinburgh, December 2009
o    Gentry-Maharaj A, Fletcher G, Sharma A, Ryan A, Burnell M, Amso N, Seif M, Turner G, Ford K, Brunell C, Rangar R, Kilkerr J, Fallowfield L, Campbell S, Jacobs I, Menon U. Postmenopausal healthy women’s experience of transvaginal ultrasound screening, British Medical Ultrasound Society Meeting, Edinburgh, December 2009
o    Gentry-Maharaj A. Preliminary screening information for UKCTOCS, Senior Staff Conference, Royal College of Obstetricians and Gynaecologists (RCOG), London, UK, 26th Nov 2009
o    Menon U, Gentry-Maharaj A, Ryan A, Burnell M, Dawnay A, Habib M, Apostolidou S, Skates S, Parmar M, Jacobs I. Serial CA125 interpreted using the Risk of Ovarian Cancer algorithm can detect ovarian cancer in absence of ultrasound abnormalities, Innovations & Progress in Healthcare for Women, 2nd International Meeting: Prevention, Screening and Risk Prediction in Women’s Health, London, November 2009
o    Fourkala E-O, Lichtenberg-Frate H, Burnell M. Gentry-Maharaj A, Hasenbrink G, Ford J, Schawarzer S, Dawnay A, Lam A, Apostolidou S, Raum E, Stegmaier C, Jacobs I, Brenner H, Widschwendter M, Menon U. Serum oestrogen receptor-alpha and beta bioactivity are associated with breast cancer Risk, Innovations & Progress in Healthcare for Women, 2nd International Meeting: Prevention, Screening and Risk Prediction in Women’s Health, London, November 2009
o    Timms J. Ovarian cancer biomarker discovery using MS-based proteomic technologies, Biotherapy Development Agency First International Meeting: Proteomics in Clinical Oncology – Possibilities, Promises and Pitfalls. Berlin, Germany, Sept 19th 2009
o    Menon U. “Managing clinical trials - the UKCTOCS experience”, Department of Biostatistics MGH Boston, USA, 27th Aug 2009
o    Menon U. “Does serum CA125 hold the key to decreasing deaths from ovarian cancer?”, 10th International Mucin Meeting, Cambridge, July 2009
o    Menon U “The prevalence screen in UKCTOCS”, Early Origins of Ovarian Cancer Symposium, Norris Cancer Centre, Los Angeles, USA, June 2009
o    Jacobs I. “The Prevalence Screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, OVACOME Members Day Meeting, London, May 2009
o    Allen P, Lanceley A, Nordin A, Gessler S, Bayne L, Hunter M, Jacobs I, Menon U “Symptoms reported by women in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, International Primary Care and Cancer Research Group Conference, Copenhagen, April 2009  
o    Gentry-Maharaj A on behalf of UKCTOCS group. “The Prevalence Screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, British Society for Gynaecological Imaging (BSGI), London, March 2009
o    Jacobs I. “The Prevalence Screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, 7th International Symposium on Advanced Ovarian Cancer, Valencia, Spain, February 2009
o    Jacobs I. Hearing the Ovarian Cancer Whisper – Lecture, San Antonio, USA, January 2009
o    Gentry-Maharaj A on behalf of UKCTOCS group. “The Prevalence Screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, Controversies of ovarian cancer screening, Geneva, Switzerland, January 2009

2008

o    Allen P, Lanceley A, Nordin A, Gessler S, Bayne L, Hunter M, Jacobs I, Menon U “Symptoms reported by women in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, Institute for Women’s Health 4th Annual Meeting, London, December 2008  
o    Menon U. “The prevalence screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening”, 7th Biennial Ovarian Cancer Research Symposium, Seattle, USA, September 2008
o    Gentry-Maharaj A on behalf of UKCTOCS group. “United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, Beckman Coulter Symposium, London, July 2008
o    Menon U. “Innovative approaches to management of clinical trials - the UKCTOCS experience”, Junior Oncology Club, Royal Society, London, June 2008
o    Gentry-Maharaj A, Ryan A, Brusati L, Nayak N, Burnell M, Sharma A, Lanceley A, Fraser L, Jacobs I, Hunter M, Menon U for UKCTOCS. ”Trends in HRT and non-HRT use in postmenopausal women in the UK”, International Menopause Society (IMS) meeting, Madrid, May 2008
o    Menon U. “Screening for Ovarian Cancer”, 2nd World Congress on Mild Approaches in Assisted Reproduction organised by the International Society for Mild Approaches to Assisted Reproduction, London, April 2008
o    Menon U. “The state of art in ovarian cancer screening”, Innovations & Progress in Healthcare for Women, 1st International Conference of the UCL Institute for Women’s Health, London, April 2008

2007

o    Sharma A, Campbell S, Gentry-Maharaj A, Burnell M, Ryan A, Hallett R, Jacobs IJ, Menon U. for United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). “Ovarian inclusion cysts – what is their malignant potential?”, European Society of Gynaecological Oncology (ESGO), Berlin, October 2007
o    Hallett RL, Singh N, Reynolds K, Gentry-Maharaj A, Burnell M, Ryan A, Sharma A, Parmar M, Jacobs IJ, Menon U for United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). “Importance of independent review of diagnosis in research trials involving cases of ovarian and primary peritoneal cancer”, European Society of Gynaecological Oncology (ESGO), Berlin, October 2007
o    Burnell M, Parmar M, Ryan A, Gentry-Maharaj A, Hallett R, Sharma A, Jacobs IJ, Menon U. for UKCTOCS. “Evidence of a healthy volunteer effect in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, European Society of Gynaecological Oncology (ESGO), Berlin, October 2007
o    Camuzeaux S, Kabir M, Burford B, Nouretdinov I, Vovk V, Ford J, Luo Z, Gentry-Maharaj A, Waterfield M, Menon U, Gammerman A, Timms J.F,  Jacobs I. “Ovarian cancer serum biomarker discovery using maldi-tof ms proteomic profiling”, European Society of Gynaecological Oncology (ESGO), Berlin, October 2007
o    Jacobs I, Menon U for the UKCTOCS Group. “Sensitivity, specificity and stage distribution at initial screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”, European Society of Gynaecological Oncology (ESGO), Berlin, October 2007
o    Menon U. “Update on UKCTOCS Trial”, Female Malignancies - Imaging, Screening, Managing, Treatment Meeting, Institute of Physics in London, May 2007

MEDIA COVERAGE

NEWS

  • Blood test “boost” in ovarian cancer fight (BBC News web Pages; Tuesday 5 May 2015)

http://www.bbc.co.uk/news/health-32530339

  • New ovarian cancer test twice as effective as existing methods (The Guardian; Monday 4 May 2015)

http://www.theguardian.com/science/2015/may/04/ovarian-cancer-test-trial-women-protein-blood

  • Skirt size increase linked to breast cancer risk, says study (BBC News web pages; Thursday 25 September 2014)

http://www.bbc.co.uk/news/health-29351249

  • Skirt size increase ups breast cancer risk (NHS news; Thursday, 25 September 2014)

http://www.nhs.uk/news/2014/09September/Pages/Skirt-size-increases-ups-breast-cancer-risk.aspx

  • Ovarian cancer screening - (NHS News; March 11 2009)

www.nhs.uk/news/2009/03March/Pages/OvarianCancerScreeningTrial.aspx

  • Trials offer ovarian cancer hope (BBC News Web pages; Wednesday 9 March 2009

news.bbc.co.uk/1/hi/health/7934784.stm

  • Ovarian cancer screening on trial (The Guardian; Wednesday 22 March 2000; page 7)

www.guardian.co.uk/Archive/Article/0,4273,3976839,00.html

  • Cancer screening trials to begin (BBC News web pages; Tuesday 21 March 2000)

news.bbc.co.uk/1/hi/health/684131.stm

Back to Top

Page last modified on 27 oct 15 12:58